Orchestra BioMed (OBIO) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Upstream Bio (UPB) over the past year, gaining 97.6% versus a loss of 76.0%. Orchestra BioMed is the larger company by market cap ($344.4 million vs $249.2 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBIO | UPB |
|---|---|---|
| Share price | $5.73 | $4.55 |
| Market cap | $344.40M | $249.21M |
| 1-day change | +1.24% | -1.30% |
| YTD return | +38.07% | -83.24% |
| 1-year return | +97.59% | -75.95% |
| 5-year return | -41.83% | — |
| EPS (TTM) | $-0.86 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.50 | $33.68 |
| 52-week low | $2.86 | $4.37 |
| Distance from 52-week high | -11.85% | -86.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +116.93% | +584.40% |
| Average volume | 299.84K | 610.08K |
| Shares outstanding | 60.11M | 54.77M |
| Employees | 86 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed UPB by 173.5 percentage points over the past year.
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Healthcare · Biotechnology · 86 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
OBIO vs UPB FAQ
Which is bigger, Orchestra BioMed or Upstream Bio?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $344.40M compared with $249.21M for Upstream Bio (UPB).
Which stock has performed better over the past year, OBIO or UPB?
OBIO returned +97.59% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Orchestra BioMed and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.